Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Cholecalciferol Vit D3

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Active Not Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07903909Not ApplicableCompletedPrimary

Effect of Cholecalciferol on Mucin-1 Levels in Urinary Extracelllular Vesicles in Individuals With Autosomal Dominant Tubulo-Interstitial Kidney Disease Due to MUC1 Mutations (ADTKD-MUC1)

NCT07816874Active Not Recruiting

Model Development and Application Based on Renal Pathology Images

Showing all 2 trials

Research Network

Common Treatments

  • Cholecalciferol Vit D31

Active Sponsors

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1
  • Gregory Papagregoriou1
  • Broad Institute of MIT and Harvard1

Top Investigators

Related Conditions

  • Glomerular Diseases1
  • Iga Nephropathy Igan1
  • Kidney Diseases Chronic1
  • Muc1 Kidney Disease1
  • Membranous Nephropathy1

Activity Timeline